SOURCE: Business Review USA

Business Review USA

May 18, 2011 17:19 ET

Spiro Rombotis, President and CEO of Cyclacel Pharmaceuticals, Reveals the Secrets to Becoming a Small Company With Huge Potential With Business Review USA

SAN DIEGO, CA--(Marketwire - May 18, 2011) - In an interview with Business Review USA, Spiro Rombotis, President and CEO of Cyclacel Pharmaceuticals, discusses how the company has become a world leader in understanding the biological mechanisms that affect the cancer cell cycle.

Cyclacel is leading the pharmaceutical industry in the development of an oral drug for Acute Myeloid Leukemia (AML) called sapacitabine and another oral drug called seliciclib, which is most advanced in trials of patients with terminal lung cancer. "Very few biotech companies are fortunate to develop a cancer drug that reaches the market. Even fewer get to do it twice," says Rombotis in the interview.

Read the full article, here.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a drug discovery and development company specializing in cell cycle biology. The discovery of cancer suppressing gene mechanisms and their role were awarded the 2001 Nobel Prize for Medicine. The most famous of these genes, p53, was discovered by Professor David Lane, who founded Cyclacel in 1996. Visit for more information.

About Business Review USA

Business Review USA is a leading digital media source of news and content for C-level executives focused on business and industry-specific news throughout the United States. Business Review USA is the territory-dedicated arm of the White Digital Media Group. Founded in 2007 by entrepreneur Glen White, White Digital Media retains a diversified portfolio of websites, magazines, daily news feeds and weekly e-newsletters that leverage technology to innovatively deliver high-quality content, analytical data, and industry news.

Business Review USA is headquartered in San Diego, California, with an additional office in Boston. For more information, contact 1-760-827-7800 or visit

Contact Information